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Protein kinases are intensely studied mediators of
cellular signaling, yet important questions remain
regarding their regulation and in vivo properties.
Here, we use a probe-based chemoprotemics plat-
form to profile several well studied kinase inhibitors
against >200 kinases in native cell proteomes and
reveal biological targets for some of these inhibitors.
Several striking differences were identified between
native and recombinant kinase inhibitory profiles, in
particular, for the Raf kinases. The native kinase
binding profiles presented here closely mirror the
cellular activity of these inhibitors, even when the
inhibition profiles differ dramatically from recombi-
nant assay results. Additionally, Raf activation
events could be detected on live cell treatment with
inhibitors. These studies highlight the complexities
of protein kinase behavior in the cellular context
and demonstrate that profiling with only recombi-
nant/purified enzymes can be misleading.INTRODUCTION
Protein kinases are found in all forms of life and are the largest
enzyme family in mammals (Manning et al., 2002). Nearly all
signal transduction pathways rely on protein kinase cascades
that tightly regulate processes such cell division, differentiation,
activation, and migration. Efforts to generate selective and
efficacious kinase-targeted drugs resulted in the first clinically
approved kinase inhibitor, Gleevec, in 2001 for the treatment
of chronic myelogenous leukemia (Cohen et al., 2002). The
success of Gleevec and the promise of protein kinases as
therapeutic targets in other disease areas have rapidly expanded
pharmaceutical research efforts on kinase inhibitors and
supported a growing industry of kinase assay methodologies
and research tools (Cohen, 2002; Noble et al., 2004).
Most kinase inhibitors that have been approved or are
currently in clinical development are competitive inhibitors of
ATP binding. However, >500 human protein kinases are knownChemistry & Biology 18,and they share high structural conservation in the ATP-binding
site. Therefore, achieving a significant degree of target selectivity
via the ATP binding site is an imposing problem (Toledo et al.,
1999; Garcia-Echeverria et al., 2000). This challenge has been
met for several compounds, such as lapatinib, which shows
impressive selectivity for epidermal growth factor receptor
(EGFR) (Karaman et al., 2008). Nonetheless, it should be noted
that the vast majority of ATP-competitive kinase inhibitor have
only been approved for the treatment of cancer, where otherwise
unacceptable toxicities can often be managed.
Rapid and cost-effective assays for nearly every human
protein kinase are now available due to the combined efforts of
academic and industrial research. Many different assaymethod-
ologies exist and most of these rely on recombinant expression
and purification of the kinase of interest or a catalytically active
fragment. The biological functions of most kinases, however,
are regulated by dynamic, posttranslational mechanisms in cells.
These regulatory events have also been shown to require
kinases to exist in physical complexes with their substrates
and/or partner kinases that allow for spatial and temporal regu-
lation (Garrington and Johnson, 1999; Newton, 2001). Although
kinase assay methodologies using recombinant enzymes are
clearly valuable tools, these methods are not capable of
capturing the complexity of kinase function and regulation
seen in native biological systems. Thus, most kinase-directed
medicinal chemistry efforts instead rely on cellular assays that
report on the kinase of interest as a primary means of deducing
structure-activity relationships.
Chemical proteomics (chemoproteomic) methodologies have
been developed recently for evaluating small-molecule binding
to protein kinases in native systems, such as in cell or tissue
lysates. Two reported methods rely on the attachment of kinase
inhibitors to solid supports (Godl et al., 2003; Bantscheff et al.,
2007; Sharma et al., 2009). The methods described by
Bantscheff et al. (2007) and Sharma et al. (2009) use broadly-
selective kinase inhibitors tethered to a solid support to capture
and evaluate more than 200 kinases from cell lysates. These
kinases can be competed off the support through the addition
of select inhibitors and thus selectivity can be evaluated. A
similar method was described by Godl et al. (2003) that
involves the attachment of a selected inhibitor to a solid
support (typically through biotin attachment), permitting affinity
enrichment of the kinase targets of the compound. Using both699–710, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 699
Chemistry & Biology
In Situ Native Kinase Profilingof the above methods, quantitative inhibitor binding information
can be obtained through the use of isotopic labeling strategies
(Bantscheff et al., 2007; Sharma et al., 2009). We have reported
an alternative method for profiling kinases in native systems,
termed KiNativ, that utilizes soluble chemical probes comprised
of ATP and ADP linked to biotin through an acyl-phosphate bond
(Patricelli et al., 2007). These probes covalently modify
conserved lysine residues in the ATP binding site of essentially
all protein kinases in addition to labeling active-site lysine resi-
dues in other ATP binding proteins. When coupled with a mass
spectrometry (MS) based analysis platform, these probes enable
the detection and characterization of >300 endogenous protein
and lipid kinases, as well as hundreds of other nucleotide-
dependent enzymes. We have also previously described
the detection of 60 kinases from a single cell line, with 40 of
these exhibiting adequate signal for quantification (Patricelli
et al., 2007). In this study, we present several fundamental
improvements to the platform that have enabled efficient
measurement of binding constants for small-molecules against
>150 protein kinases in parallel, using only a single cell line,
and >200 total kinases from two cell lines. Binding constants
are presented for ATP as well as several research and clinical-
stage kinase inhibitors. Notably, we reveal that kinases can
show strikingly different inhibitor sensitivity profiles in native
versus recombinant systems and demonstrate that the cellular
efficacy of these kinase inhibitors is accurately predicted by
KiNativ.
RESULTS
Rationale for and Development of Kinase-Focused MS
‘‘Target Lists’’
We previously found that biotin-tagged acyl-phosphates of ATP
and ADP are capable of acylating the conserved active site
lysines in a broad range of known human protein and lipid
kinases as well as other ATP-dependent enzymes (Figures 1A
and 1B) (Patricelli et al., 2007). The reaction of these probes
with their target kinases can be quantitatively monitored by
digesting the treated cell-lysates with a protease (trypsin),
affinity-enriching the biotinylated peptides on streptavidin
beads, and analyzing the resulting labeled peptides by liquid
chromatography-tandem MS (Figure 1C). Although our original
protocols were adequate for illustrating the usefulness of acyl-
phosphates as kinase affinity probes, further optimization was
required to maximize the scope and utility of this method.
The most critical issues for the optimization of KiNativ were to
improve the sensitivity and accuracy of quantification. Our initial
protocols were developed to analyze biotin-labeled peptides in
‘‘data-dependent’’ mode on an ion-trap mass spectrometer. In
this acquisition mode, themass spectrometer requires the signal
strength in the parent ion (MS) spectrum to be in the top 10–20
ions before a fragment spectrum is collected. With the acyl-
phosphate probes used in these studies as many as 1000
different probe-labeled peptides can be detected in a given
sample and many of the active site protein kinase peptides are
present at very low levels relative to other labeled ATPases.
These factors contributed to poor reproducibility and sensitivity
in the data-dependent MS mode, particularly for low abundance
species in complex mixtures. To overcome these limitations, we700 Chemistry & Biology 18, 699–710, June 24, 2011 ª2011 Elsevierdeveloped a ‘‘targeted’’ MS approach on a linear ion trap mass
spectrometer, whereby the instrument is preprogramed to
collect MS/MS data on known kinase peptide ions at specified
times (Figure 1D). This approach is analogous to multiple-
reaction-monitoring (MRM) using triple-quadrupole mass spec-
trometers and has recently garnered interest in its application
to proteomics experiments using ion trap mass spectrometers
(Schmidt et al., 2009; Domon and Aebersold, 2010).
This targeted approach requires a priori knowledge of the
kinase proteins expressed in the sample (cell lysate) of interest,
which we obtained by performing exhaustive data dependent
analyses with both ATP and ADP acyl-phosphate probes.
Analysis of HL60 and PC3 cell lysates yielded data on approxi-
mately 160 kinases per cell line and 220 kinases in total.
Based on these data sets, parent ions corresponding to each
kinase were selected for targeting and assembled into time-
segmented target lists specific for each probe-proteome combi-
nation. It should be noted that scan rate limitations for the MS
instrumentation used here limited the total number of ions tar-
geted in a given run. Therefore, a subset of labeled proteins
(e.g., kinases) was selected such that a coherent data set of
related enzymes would result. Similar target lists for other
probe-labeled enzyme families are currently under development.
Data collected using the kinase target lists described above
was analyzed by extracting characteristic fragment ions for
each kinase peptide. Using this approach, we found that the
signal/noise ratio of the summed fragment ion traces from the
targeted MS/MS spectra were typically 50-fold higher than
the signal/noise ratio of the corresponding parent ion chromato-
grams in the MS scans (only parent ion/MS data is available for
signal quantitation in data-dependent MS runs) (Figure 1D). In
many cases, robust, clean peaks could be extracted from
MS/MS spectra when no peak could be detected in the MS
scans. Using a single proteome and either the ATP or ADP
probe, >100 kinases could be detected with sufficient signal to
allow for robust quantitation. Both probes are used in most
studies due to slight variations in the coverage and labeling
efficiency between probes (Patricelli et al., 2007). Overall, this
targeted method dramatically improved the detection and
quantitation of acylphosphate probe-labeled kinases.
Profiling ATP and Kinase Inhibitors with KiNativ
One of our major goals was to accurately determine binding
constants for kinase inhibitors against native kinases. In any
competitive, activity-based profiling method, a critical consider-
ation is the effect of probe binding and irreversible labeling
kinetics on the observed inhibition by a reversible inhibitor
(Leung et al., 2003). Observed IC50 values can be dramatically
shifted from true Kd values if the probe concentration is too
high or the reaction time is too long. We addressed this
potential complication by determining IC50 values for ATP
binding under both high (20 mM) and low (1 mM) probe labeling
conditions. The results of this analysis allowed for the selection
of a probe concentration (5 mM) and labeling time (10 min)
where >90% of the kinase targets showed a <3-fold shift
between ATP IC50 and the apparent Kd (Kd
app) value. Addition-
ally, for kinases showing probe-related IC50 shifts, themagnitude
of the shift was determined so that the IC50 could be corrected to
yield an accurate Kd
app value (see Experimental Procedures) It isLtd All rights reserved
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Figure 1. The KiNativ Method
(A) Chemical structure of the acylphosphate probe.
(B) Schematic of the KiNativ method. Protein lysates are treated with an inhibitor followed by addition of the desthiobiotinylated acylphosphate-nucleotide probe.
After a tryptic digest and streptavidin enrichment, the probe labeled peptides are characterized and quantified using a targeted LC-MS2 strategy.
(C) Model of an acylphosphate probe bound in the active site of CDK2 (PDB ID 1HCK). Conserved, catalytic lysine residues are illustrated.
(D) Signal enhancement through targeted LC-MS2 analysis. Signals fromMS1 (or parent) ion signals typically used for quantification in nontargeted runs (top) are
compared to extracted MS/MS ions from a targeted LC-MS2 run (bottom).
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app value may differ from a Kd value
obtained using purified recombinant kinase binding or activity
assays due to a variety of assay specific factors including
differences in endogenous/full length versus truncated kinase
constructs, conformation and/or activation states, protein-
protein interactions, etc. It is also likely that kinase conformations
and activation states in both recombinant enzyme preparations
and cell lysates are heterogeneous. The possibility therefore
exists that the differential sensitivity of various assays to subpop-
ulations of enzyme may skew the results of the ensemble
average or mask the response of subpopulations that do not
significantly contribute to the measured signal. However, theChemistry & Biology 18,Kd
app determined here should represent the occupancy of
the probe accessible enzyme population within a biological
background.
Table 1 shows selected results from the profiling of ATP,
staurosporine, dasatinib (Sprycel), imatinib (Gleevec), erlotinib
(Tarceva), BIRB796, and sorafenib (Nexavar) in HL60 and PC3
lysates. These compounds are all ATP competitive kinase
inhibitors and represent examples of both Type I (DFG-in) and
Type II (DFG-out) binding preferences (Liu and Gray, 2006).
The complete data set is presented in Table S1 available
online. It is important to note that, before addition of either
exogenous ATP or an inhibitor, the cell lysates are subjected to699–710, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 701
Table 1. Inhibition Profiles for Reference Compounds and Clinically Relevant Kinase Inhibitors
Kinase name ATP Kd
app Staurosporine Dasatinib Erlotinib BIRB796 Sorafenib Imatinib
ABL1/2 5.2 13 0.0067, 0.0034 >10 >10 >10 0.21, 0.15
ACK 22 0.062 0.033 >10 >10 >10 >10
AurA/B/C 9.5 0.076 >10 7.4 >10 >10 >10
AurB 31 0.03, 0.012 >10, >4 6.4, 2.6 >10, >4 >10, >4 >10, >4
BRAF 6.1 >10 3.2 >10 >10 >10 >10
BTK 86 0.91 0.013 >10 >10 >10 >10
CDK5 13 0.64 >10 >10 >10 >10 10
CDK8/11 19 2.2 >10 >10 >10 >10 11
CSK 17 2.9, 2.4 0.015, 0.012 >10 >10 >10 >10
EGFR 18 >10 4.7, 4.1 0.3, 0.19 >10 >10 >10
EphA1 1.7 4.3 0.022 >10 >10 >10 >10
EphA2 22 11 0.017 >10 >10 >10 >10
EphB2 5.2 10 0.014 >10 >10 >10 >10
EphB4 8.5 >10 0.0028 5.2 >10 >10 >10
FGR 2.6 0.92, 0.37 0.0068, 0.0027 >10, >4 >10, >4 >10, >4 >10, >4
FYN ND 0.27, ND ND 5.8, ND ND >10, ND ND
GCK 26 0.1 5 >10 >10 >10 >10
GCN2 92 1.3, 1.1 >10 0.76, 0.6 >10 >10 >10
HCK 10 0.43 0.015 >10 >10 >10 >10
ILK 57 >10 0.24 1.1 >10 >10 >10
IRAK3 360 0.012 10 >10 >10 >10 ND
JAK1 (Domain 2) 1.8 0.21, 0.051 5.3, 1.3 >10, >2.5 10, >2.5 >10, >2.5 >10, >2.5
JNK1/2/3 19 9.2 >10 >10 0.087 >10 8.6
JNK2 ND 3.1 >10 >10 0.029 >10 5.3
KHS1 9.6 0.12 0.4 >10 >10 >10 >10
KHS1/2 7.8 0.23 2.2 >10 >10 >10 >10
LOK 12 0.012 10 1.2 1 5.3 >10
LYN 1 0.41 0.0031 >10 >10 >10 >10
MAP2K1 8.1 0.49, 0.2 10, 4 >10, >4 >10, >4 ND >10, >4
MAP2K5 2.6 2.6, 1.4 0.058, 0.037 10 >10 >10 >10
MAP3K1 64 10 0.49 0.63 >10 0.82 >10
MAP3K2 7.9 1 6.5 >10 >10 >10 >10
MAP3K4 20 >10 0.51 >10 >10 >10 >10
MET 74 0.63, 0.67 >10 3.5, 2.4 >10 >10 >10
MINK,HGK,TNIK 7.6 0.11 >10 >10 1.1 >10 >10
MLKL 150 >10 3.2 >10 >10 >10 >10
p38a 570 >10 0.77 >10 0.19 2.4 >10
p38d/g 300 1.3 >10 >10 0.45 >10 >10
PIK3C3 97 >10 >10 >10 >10 >10 9.5
PIP5K2c 63 >10 >10 3.7 >10 >10 1.5
PIP5K3 7 10 >10 >10 >10 >10 4.2
PYK2 70 0.2 >10 >10 9 >10 >10
QSK 20 0.12 0.39 >10 >10 >10 >10
SLK 3.8 0.0091 >10 0.58 >10 >10 >10
SRC 9.8 0.89 0.0033 >10 >10 >10 >10
STLK5 54 >10 0.64, 0.21 >10 >10 >10 >10
SYK 3.2 0.045 10 >10 >10 >10 >10
TAO2 1.1 0.71, 0.46 >10 >10 >10 7.1, 2.8 >10
TEC ND >10, ND 0.55, <0.079 >10, ND 10, ND >10, ND >10, ND
Chemistry & Biology
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Table 1. Continued
Kinase name ATP Kd
app Staurosporine Dasatinib Erlotinib BIRB796 Sorafenib Imatinib
YES 31 1.1 0.0032 >10 >10 >10 >10
ZAK 19 10 0.1445 >10 5.4 0.103 >10
Selected results are illustrated from the profiling of ATP, staurosporine, dasatinib (Sprycel), imatinib (Gleevec), erlotinib (Tarceva), BIRB796, and sor-
afenib (Nexavar) in HL60 and PC3 proteomes. Data are shown where significant inhibition with the clinically relevant kinase inhibitors was observed.
The data was generated with a 15-min preincubation. Approximately 220 kinases were evaluated for inhibitory activity. ND, not determined. See also
Table S1 and Figures S1–S3.
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competing factors. Approximately 220 kinases were profiled in
total, with >400 total data points per compound when redun-
dancies between cell/probe target lists are considered
(complete table in Table S1). Internal consistency between
redundant data points was excellent with most cases showing
IC50/Kd
app values within a 2-fold margin. It should be noted
that although the data presented in Table 1 illustrate the Kd
app
for the enzymes profiled, all other data presented in this article
will be presented as an IC50 values (as indicated). For the vast
majority of enzyme/probe combinations the relative shift
between the IC50 and Kd
app is <3, therefore the IC50 data are
close approximations of the Kd
app.
Several efforts were made to further validate the method and
resulting IC50 values. First, to demonstrate the linearity of signal
response, a recombinant kinase (ErbB2) was spiked into a back-
ground proteome absent of the spiked kinase (HL60 lysate) and
the integrated signal was measured (Figure S1A). As expected,
the integrated signal response was linear down to a signal/
noise ratio of 3. Second, to verify that the measured IC50
values are representative of the actual Kd
app values, we
evaluated the effect of probe concentration on staurosporine
IC50 values in a second cell line (A375 cell lysate) (Figure S1B
and Table S2). As predicted, the majority of the data did not
demonstrate a >3-fold shift in IC50 value. We further demon-
strated that the IC50 values are independent of protein concen-
tration by comparing IC50 values obtained at two protein
concentrations (Figure S1C). Finally, measured IC50 values for
staurosporine were compared between multiple cell lines and
probe types and were found to be in excellent agreement with
one another (Figures S1D and S1E). Replicate data from
profiling a Raf inhibitor, PLX4720, also showed excellentTable 2. Correlation between Cellular Efficacy and KiNativ Measur
Target Cellular Efficacy EC50 (nM) KiNativ IC
Dasatinib Abl1/2 1.5 3.4
Dasatinib SRC 4.3 3.3
Imatinib Abl1/2 200 150
BIRB796 p38 30 11a
BIRB796 JNK 1000 87
SB203580 p38 280 85
Erlotinib EGFR 24.5 18
Staurosporine PKC 30 27
The type of cellular assay from each reference is listed. When possible, r
inhibitor activity rather than downstream cellular response (e.g., cell viabilit
a The value used is calculated from the 4-hr preincubation data.
Chemistry & Biology 18,agreement between measurements (Figure S1F and Table S3).
Overall, these data support that the IC50 values presented here
are typically reproducible within a 2-fold margin.
For broad-spectrum kinase inhibitors such as staurosporine,
comprehensive data are available from recombinant enzyme
assays and could be used as another form of validation. Overall,
Kd
app values for staurosporine measured by the probe-based
assay, were on the order of 10–20-fold weaker than Kd values
determined for purified recombinant kinases in activity or binding
assays (Figure S2). However, if this general shift is taken into
account, the correlation of relative potency between the
methods is reasonably robust. It is interesting to note that the
reported in vivo potency of staurosporine against PMA-
induced PKCa signaling (Table 2) (Winkler et al., 1988), is
essentially identical to the Kd
app value and is 14-fold higher
than the staurosporine IC50 determined in a recombinant kinase
assay (www.invitrogen.com). Moreover, a robust correlation
between the Kd
app and cellular efficacy was observed for those
inhibitors where the cellular efficacy could be corroborated
(Table 2).
Erlotinib Selectively Inhibits Membrane-Bound over
Detergent-Solubilized EGFR
In our initial evaluation of erlotinib inhibitory activity, it was
observed that the Kd
app for erlotinib against EGFR in PC3 cells
(0.19 mM) (Figure S3) was considerably higher than the
reported literature values for cellular EGFR potency (4–20 nM)
(Carey et al., 2006; Schiffer et al., 2007). To further investigate
this observation, we explored solubilized and intact membrane
samples from resting and EGF stimulated MDA-MB-231 cells
that express EGFR at higher levels than PC3 cells (Table S4).
Additionally, a lower probe dose (1 mM) was used becauseed IC50 Values
50 (nM) Cellular Assay Type Reference
Abl autophosphorylation Manley et al. (2005)
SRC autophosphorylation Du et al.(2009)
Abl autophosphorylation Manley et al. (2005)
MapKap-K2 phosphorylation Kuma et al. (2005)
c-Jun Phosphorylation Kuma et al. (2005)
TNF-a release Mihara et al. (2005)
EGFR autophosphorylation Carey et al. (2006)
Ca+2 mobilization Winkler et al. (1988)
eferences were selected that demonstrated the most direct measure of
y or proliferation).
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Figure 2. Dasatinib Inhibits MAP2K5
HeLa cells were treated with varying concentrations of dasatinib for 1 hr before
treatment with EGF. Cells lysates were analyzed by amobility shift western blot
for phosphorylation of ERK5, a substrate of MAP2K5. See also Figure S4.
Chemistry & Biology
In Situ Native Kinase ProfilingEGFR was found to show a3-fold shift of IC50 from Kdapp at the
standard 5 mM probe dose. Consistent with the data collected in
detergent solubilized PC3 cell lysates, 0.1 mM erlotinib did not
significantly inhibit EGFR in detergent solubilized lysates from
MDA-MB-231 cells. In contrast, EGFR from intact membrane
preparations of MDA-MB-231 cells was inhibited and a slight
increase in potency was observed after 5 min cellular stimulation
with 500 ng/ml EGF (Table S4). Thus, when the conditions of
cellular efficacy are closely replicated (i.e., intact membranes
and activated EGFR), the potency of erlotinib against EGFR
determined here closely matches reported cellular efficacy
(Table 2).
Dasatinib Is an Inhibitor of MAP2K5
Dasatinib is a clinically approveddrug that is apotent inhibitor of a
large number of tyrosine kinases and shows a predilection for
kinases possessing a ‘‘gatekeeper’’ threonine residue (Hantschel
et al., 2007). The kinase targets of dasatinib have been evaluated
using recombinant enzyme panels, phage display methods,
and chemical proteomic approaches (Bantscheff et al., 2007;
Karaman et al., 2008). In addition to confirming many of the
known targets of dasatinib, our profiles identified MAP2K5 as
an unreported, potent target of dasatinib (Kd
app = 37 nM)
(Figure S4). MAP2K5 is unusual among the MAP2K kinases in
that it forms a signaling complex with ERK5. To test whether
the observed binding of dasatinib to MAP2K5 would translate
into cellular inhibition of ERK5 phosphorylation, EGF-stimulated
HeLa cells were treated with various concentrations of dasatinib
and the level of ERK5 phosphorylation was quantified (Figure 2).
For thoroughness, an additional cell line (A549) was evaluated to
corroborate MAP2K5 as a target of dasatinib and the inhibition of
MAP2K5 was confirmed (Figure S4D). The HeLa cell experiment
demonstrated that dasatinib inhibited phosphorylation of ERK5
with a cellular EC50 of 0.56 mM and further illustrates that
KiNativ profiling can identify new kinase-inhibitor interactions,
even for inhibitors that have been subject to extensive profiling
by other approaches. The most comprehensive published
profile of dasatanib did not cover MAP2K5 despite the fact
that >300 protein kinases were profiled (Karaman et al., 2008).
Additionally, of the MAP2K isoforms present in that study
(MAP2K1,2,3,4,6), only MAP2K1 and MAP2K2 were weakly
inhibited by dasatinib. Interestingly, the only literature report we
have found showing any affinity of dasatinib for Map2K5 was
from an alternate chemical proteomics approach (Bantscheff
et al., 2007) where an IC50 value of 1.2 mM was observed.
Importantly, later work has shown that the IC50 values from this
study were systematically affected by assay properties (similar
to the kinetic issues possible with our probes), and thus may704 Chemistry & Biology 18, 699–710, June 24, 2011 ª2011 Elseviernot have reflected true binding potencies (Sharma et al., 2009).
Further, the relatively poor affinity observed in the study by
Bantscheff et al. (2007) did not suggest Map2K5 as a significant
or noteworthy target relative to other targets of the compounds.
Comparison of Native and Recombinant Raf Kinases
A surprising discovery from the inhibitor profiles (Table 1) was the
lack of B-Raf inhibition by sorafenib. Sorafenib was initially
developed as a Raf kinase inhibitor and consistently showed
good potency against Raf kinases in recombinant assays
(Wilhelm et al., 2004). To further investigate the possible
differences between native and recombinant Raf kinases we
selected two well-studied compounds, GW5074 (Lackey et al.,
2000) and SB203580 (Cuenda et al., 1995), with reported Raf
activities as well as two more recently developed B-Raf
inhibitors, PLX4720 (Tsai et al., 2008) and SB590885 (Takle
et al., 2006). Chemical structures for the Raf inhibitors are
presented in Figure S5. GW5074 has also widely been reported
as a Raf-1 (C-Raf) selective inhibitor, however, early studies did
not assess potency of this compound against A-Raf or B-Raf.
Recent reports have shown that GW5074 has potent activity
against B-Raf in recombinant kinase assays (Kupcho et al.,
2008). SB203580 is a well studied, relatively selective inhibitor
of p38 kinases; however, recombinant profiling efforts have
found moderate B-Raf inhibition (Karaman et al., 2008).
PLX4720 and SB890885 have both been shown to exert potent
B-Raf inhibition in recombinant and cellular assays. For all five
compounds, we determined binding to recombinant and native
B-Raf (Table 3, columns 2 and 4), V600E-B-Raf (Table 3,
columns 3 and 5), Raf-1 (Table 4, column 2 and 3), and A-Raf
(Table 4, column 4). KiNativ evaluation of native wild-type (WT)
B-Raf was determined in HL60 cells, whereas V600E-B-Raf,
Raf-1, and A-Raf were monitored in the A375 melanoma cell
line that expresses the V600E-B-Raf mutation. All Raf probe
labeling experiments were performed using the ATP-based
probe and example data illustrating PLX4720 inhibition of the
Raf kinases are presented in Figure S6. Recombinant Raf
assays were performed by monitoring recombinant MAP2K1
phosphorylation at S218/222 by western blotting. Cellular
activity of the five compounds was determined using both
cellular proliferation inhibition assays (Table 3, column 7), and
phospho-ERK1/2 inhibition assays (Figure S7) in the A375
melanoma cell line.
The inhibitor sensitivity profiles measured in our recombinant
Raf assays agreed well with reported literature values. However,
the ability of these compounds to inhibit ERK1/2 phosphoryla-
tion and proliferation in A375 cells was not well predicted by
the in vitro/recombinant kinase assays. For example, GW5074
and SB590885 exhibited nearly identical potencies against
recombinant V600E-B-Raf (24 nM and 43 nM, respectively),
however, GW5074 was >300-fold weaker (EC50 > 10 mM) in the
cellular proliferation assay than SB590885 (EC50 = 0.03 mM).
SB590885 was also a dramatically more potent inhibitor of
ERK1/2 phosphorylation in vivo than GW5074. In contrast to
the recombinant assay results, the in vivo p-ERK1/2 inhibition
and antiproliferative activity of the Raf inhibitors was highly
consistent with their behavior against native V600E-B-Raf
measured here. For example, the dramatic cellular potency
difference observed for SB590885 and GW5074 nicely matchedLtd All rights reserved
Table 3. Inhibitory Activity of Raf Inhibitors Evaluated against Multiple B-Raf Isoforms
Assay Format In Vitro MAP2K1 Phos. KiNativ KiNativ Cellular Proliferation
Enzyme Source Recombinant HL60 A375 Recombinant A375
Kinase WT-B-Raf V600E-B-Raf WT-B-Raf V600E-B-Raf V600E-B-Raf V600E-B-Raf
Sorafenib 0.63 0.18 >10 >10 ND 4
SB203580 0.69 0.309 >10 4.7 ND >10
GW5074 0.011 0.024 >10 2.6 0.16 >10
SB590885 0.004 0.043 0.1 0.006 ND 0.03
PLX4720 0.053 0.09 0.05 0.008 1.3 0.03
Several Raf inhibitors were evaluated in an in vitro phosphorylation assay using recombinant B-Raf, by KiNativ using both recombinant B-Raf
and endogenously expressed enzyme (both wild-type and V600E isoforms), and in a cellular proliferation assay using endogenously expressed
V600E-B-Raf. ND, not determined. See also Figure S4., Figure S5, Table S5, and Table S6.
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values of 2.6 mM and 0.006 mM for GW5074 and SB590885,
respectively). Overall, the native kinase binding affinity deter-
mined in KiNativ for various Raf kinase inhibitors was consistent
with the cellular antiproliferative activity and p-ERK1/2 inhibition
for all compounds tested.
To investigate the possible reasons for the dramatic difference
between V600E-B-Raf binding and the recombinant kinase
assay, we evaluated the binding of GW5074 and PLX4720 to
recombinantV600E-B-Raf using our probe-basedassay (Table 3,
column 6). GW5074 andPLX4720 showed similar relative binding
affinities compared to the MAP2K1 phosphorylation assay, with
GW5074 being 5–10-fold more potent than PLX4720 against
recombinant V600EB-Raf in both assay formats. Thus, the differ-
ence in behavior of the recombinant and native B-Raf assays
appears to reflect differences in the behavior of the recombinant
B-Raf protein, rather than only differences between the assays
themselves.
Similar to what was found for WT and V600E-B-Raf, we found
striking differences in the potencies of the five compounds
against native versus recombinant Raf-1. None of the com-
pounds tested appeared to be potent Raf-1 inhibitors based
on KiNativ measurement. A-Raf binding measurements revealed
that PLX4720 was unique among the compounds tested in being
a potent inhibitor of A-Raf. No recombinant assays have been
reported for A-Raf, so comparisons with in vitro assay systemsTable 4. Inhibitory Activity of Raf Inhibitors Against Raf-1 (C-Raf)
and A-Raf
Assay Format In Vitro MAP2K1 Phos. KiNativ
Enzyme Source Recombinant A375 A375
Kinase Raf-1 Raf-1 A-Raf
Sorafenib 0.027 >10 >10
SB203580 1.8 >10 >10
GW5074 0.021 >10 >10
SB590885 0.025 >10 >10
PLX4720 0.012 0.35 0.022
Several Raf inhibitors were evaluated against Raf-1 and A-Raf endoge-
nously expressed in A375 cells and against recombinant Raf-1 in an
in vitro phosphorylation assay. See also Figure S5, Table S5, and
Table S6.
Chemistry & Biology 18,could not bemade. Select data from the profiling of Raf inhibitors
are presented in Table S5 and the complete data set is presented
in Table S6.
Complex Behavior of Raf Kinase Signaling Pathways
To further explore the behavior of Raf kinase inhibitors and their
effects in cellular systems, we treated living A375 cells with these
compounds for 30min and thenprofiled lysates from treated cells
using the KiNativ platform (Figure 3). Before probe labeling with
the ATP-based probe, the lysates were gel-filtered to remove
any compound that hadentered the cells. In parallel experiments,
non-gel-filtered lysates were analyzed and the inhibition profiles
observed were entirely consistent with the targets observed for
these compounds in lysate profiling experiments described
above (data not shown).
Surprisingly, significant increases in Raf-1 probe-labeling
were observed in cells treated with SB590885, SB203580, and
PLX4720. PLX4720 also caused a dramatic increase in A-Raf
labeling despite the fact that PLX4720 is a potent inhibitor of
A-Raf. We believe that this paradoxical finding may be due to
a change in conformation of A-Raf that decreases its affinity
for PLX4720, however, the precise mechanism is still under
investigation. Due to the short cellular treatment time (30 min),
changes in transcription seemed an unlikely basis for the
increased probe-labeling signals. Moreover, the fact that the
inhibitors were removed before probe labeling indicates that
significant, lasting alterations to the enzyme are induced through
interaction with the inhibitor. In light of this and other work
(Hatzivassiliou et al., 2010; Poulikakos et al., 2010), the increased
labeling of A-Raf and Raf-1 is most likely due to changes in the
conformation of these kinases leading to either increased affinity
for ATP or amore optimal positioning of their catalytic lysine resi-
dues for probe labeling. These findings demonstrate that KiNativ
can detect inhibitor induced conformational changes in the ATP
binding site of native kinases within a biological context. They
also suggest that the platform could be used to distinguish inhib-
itors based on their specific effects on complex kinase signaling
pathways.
DISCUSSION
The results presented here represent the most comprehensive
analysis of the binding properties of native kinase ATP sites699–710, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 705
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Figure 3. Cellular Properties of Raf Inhibitors
A375 cells were treated with the indicated inhibitors for 30 min. Cells were
lysed, and the lysates analyzed using KiNativ. Data are plotted as the ratio of
control versus treated signal for each indicated kinase. Error bars represent
the range of duplicate data points. Data is representative of three separate
duplicate experiments.
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In Situ Native Kinase Profilingperformed to date. The improvements to the KiNativ method
achieved through the use of a targeted MS approach enable
native kinase binding measurements to be made accurately
and efficiently across >150 kinases in a single cell or tissue
type. The method can be applied to any protein source, from
any species, as long as DNA/protein sequence information is
available. We demonstrate the capability to evaluate both Type
I (DFG-in) and Type II (DFG-out) inhibitors and this method
should be applicable to any kinase inhibitors that alter access
of the probe to the ATP binding site. Through the global evalua-
tion of ATP, staurosporine, and several clinical kinase inhibitors
across >200 native kinases in two cell types (HL60 and PC3
cells), an intriguing picture of native kinase properties has
emerged. Kinase biochemistry and drug development efforts
have long relied on recombinant assays for characterization of
kinase activity and inhibition and there are many examples of
results that have been validated in vivo. However, protein
kinases universally rely on protein-protein interactions for their
function and are tightly regulated through multiple posttransla-
tional mechanisms, often involving sequence regions distant
from the protein kinase domain. Thus, it would be unreasonable
to expect reconstituted in vitro assays, often using truncated
kinase domain constructs, to provide an accurate assessment
of in vivo properties in all cases. The global comparisons of
native kinase binding properties determined here, with activity
and binding assays of purified recombinant protein kinases
demonstrated a clear correlation between binding/inhibition
measurements supporting the general utility of recombinant
kinase assays. However, the affinity of kinase inhibitors for their
targets measured using the probe-based assay in cell lysates
was often quite different from the respective values obtained
using activity or binding assays of recombinant, isolated kinase
preparations. These differences could be attributed to many
possible factors including differences in the relative propensity
of the assays to readout particular kinase conformations/activa-706 Chemistry & Biology 18, 699–710, June 24, 2011 ª2011 Elseviertion states, differences in properties of full length versus trun-
cated kinase constructs, and/or differences in the overall con-
formation of kinases in isolated systems versus the cellular
milieu. Further work will be needed to determine the cause of
these differences, and it is likely that multiple factors are at
play. Nonetheless, the data shown here support the notion that
inhibitor properties determined using the KiNativ assay are
useful for predicting and interpreting the cellular behavior of
kinase inhibitors.
No comprehensive data set of in vivo inhibitor potency against
specific kinase phosphorylation events exists to allow for a global
comparison with the profiles described here. However, the inhib-
itors discussed here have been the subject of detailed in vivo
studies and their target potencies are well documented. For im-
atinib and dasatinib, the KiNativ assay results show excellent
agreement with reported in vivo phosphorylation results against
Abl and Src (Table 2). On the other hand, initial Kd
app measures
for BIRB796 and erlotinib, were significantly weaker than
some reported cellular EC50 values. Several studies have
documented cellular potency of BIRB796 against p38a in the
low nM range (Pargellis et al., 2002; Kuma et al., 2005). However,
BIRB796 is known to be a slow binder of p38a, withmaximal inhi-
bition typically reached after 4 hr or more (Pargellis et al., 2002;
Regan et al., 2003). Preincubations of BIRB796 with cell lysates
for 4 hr showed a dramatic increase in potency (90% inhibition at
0.1 mM, data not shown) to levels consistent with in vivo potency.
Thus, the slow binding properties of BIRB796 likely account for
the initial underestimate of p38a potency.
Another somewhat surprising observation was the relatively
weak affinity of erlotinib for EGFR. Recombinant assays typically
suggest binding affinities in the low nM range (Gendreau
et al., 2007), while we determined a Kd
app of 190 nM under
our standard conditions. The initial Kd
app was measured in
detergent-solubilized membranes from PC3 cells, which are
known to have poor overall EGFR expression and are not used
as models for EGFR-induced oncogenesis. The versatility of
the KiNativ platform allowed for analysis of EGFR in an alternate
cell line, MDA-MB-231, using both intact membranes and solu-
bilized lysate preparations in either the resting state or after
EGFR activation with EGF. Surprisingly, it was observed that
the most significant shift in potency for erlotinib was found
when comparing membrane bound versus detergent solubilized
preparations. Erlotinib potency against EGFR in intact mem-
branes was 5–10-fold stronger than in solubilized preparations.
Importantly, when conditions of cellular efficacy studies were
most closely mimicked, with EGFR on intact membranes after
activation with EGF, the observed potency was consistent with
the cellular potency. This result highlights the complex nature
of small molecule-kinase interactions and demonstrates the
value of a platform like KiNativ that enables the determination
of binding constants for inhibitors against native kinases across
any cell type of interest and using wide range of conditions.
Although it is not necessarily surprising that the inhibitory
potency determined against kinases in a more native setting
would more accurately reflect in vivo behavior of compounds,
the striking correlation of the Kd
app values with in vivo potency
found here is compelling (Tables 2–4). Several important factors
distinguish the KiNativ assay from recombinant enzyme assays
and may account for the discrepancies between recombinantLtd All rights reserved
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app, and the cellular efficacy. First, full length,
endogenous enzymes are analyzed rather than the truncated
and/or tagged forms often employed in recombinant enzyme
assays. Differences in behavior between full length and trun-
cated kinases have been noted previously (Donella-Deana
et al., 1998). Second, the KiNativ IC50 values are a direct
measure of active site binding rather than a measure of
enzymatic activity. Thus, KiNativ is more a measure of the
total pool of kinase capable of interacting with the ATP/ADP
based probe, which may differ from the population of kinase
capable of supporting activity in a specific assay. Third, the
assay is performed under a setting more typical of a cellular
environment with respect to the specific complement of
proteins present and the overall protein concentrations. Thus,
inhibitors may appear less potent due to decreased effective
concentrations through either nonsaturable bulk protein affinity
or the presence of high levels of specific targets. Fourth,
posttranslational modifications and protein-protein interactions
including kinase-substrate interactions, etc. are largely pre-
served in cell lysates. The precise conformation of the kinase
active site, and/or steric accessibility of some binding sites will
likely be affected by modifications and protein-protein interac-
tions occurring in vivo and in cell lysates.
Although the data presented here support the trend that Kd
app
accurately reflects the cellular pharmacological properties of the
inhibitors examined, it is conceivable that this will not be true in
all cases. For example, if a minor subpopulation of kinase is
responsible for the majority of biological signaling, and a kinase
inhibitor is selective for this particular kinase conformation, the
KiNativ assay may not be able to detect the small change in
signal that would result from inhibitor binding to this minor
component. This potential issue highlights the complexity of
kinase biology and the value of using multiple techniques to
assess the pharmacological properties of kinase inhibitors. It is
likely that no single kinase assay format will elucidate the rele-
vant binding properties of inhibitors in every case.
Importantly, the results presented here were determined in the
absence of cellular ATP (the samples were gel-filtered before
labeling). Thus the affects of cellular ATP competition do not
account for the differences observed between recombinant
enzyme assay Kd values and the Kd
app values presented here.
The fact that kinase inhibitors typically show a R10-fold loss
of potency in cellular and/or in vivo assays when compared to
recombinant assays has commonly been attributed to competi-
tion with endogenous ATP (Knight and Shokat, 2005; Murphy
et al., 2010). However, the data presented here suggest that
even in the absence of ATP,most kinase inhibitors show reduced
potency in a more native setting relative to recombinant enzyme
assays. The fact that ATP is removed by gel-filtration before
analysis and that the measured Kd
app is in excellent quantitative
agreement with cellular efficacy in many cases, implies that
competition with endogenous ATP may be only a minor issue
for some kinases in vivo. All estimates of cellular ATP concentra-
tions that we are aware of assess the aggregate, averaged
ATP level in disrupted cellular material. It is very possible that
this bulk ATP is highly compartmentalized such that many
kinases may not experience ATP levels sufficient to cause
dramatic competition with ATP site directed inhibitors. Nonethe-
less, it is noteworthy that the Kd
app appears to be an excellentChemistry & Biology 18,predictor of cellular efficacy, and this capability affords the
KiNativ platform a unique capacity in kinase inhibitor drug
discovery/development.
Although the relative trends of inhibition observed here
agree reasonably well with recombinant assays, several outlying
data points suggest more complex behavior for particular
kinases. The three Raf kinase isoforms are a set of particularly
interesting examples in this regard. Interestingly, the first clini-
cally approved Raf kinase inhibitor, sorafenib, has more recently
been shown to exert its activity through kinase targets other than
Raf kinases (Smalley and Flaherty, 2009). Using the KiNativ
platform, we discovered that native Raf kinases show a very
different structure-activity relationship compared to their recom-
binant counterparts. Some compounds, such as PLX4720 and
SB590885, show reasonably consistent potency between re-
combinant, KiNativ, and cellular/phenotypic assays whereas
other compounds, such as sorafenib, GW5074, and SB203580,
show dramatic differences. Importantly, for all of the compound
classes, the Kd
app agrees very well with cellular phenotypic and
in vivo phosphorylation data. Thus, the differences in behavior
observed for these compounds between recombinant and
cellular assays appear to be due to differences in the precise
properties and/or conformation of the kinases in a native setting
compared to the protein conformations expressed in isolated
recombinant systems.
While exploring the behavior of Raf kinases, a second powerful
property of the KiNativ platform became apparent. Recent
literature reports have noted the ability of some Raf kinase inhib-
itors, namely SB203580 (Hall-Jackson et al., 1999a, 1999b),
SB590885(Heidorn et al., 2010), and PLX4720 (Hatzivassiliou
et al., 2010; Poulikakos et al., 2010), to cause a paradoxical acti-
vation of Raf-1 in cellular settings. The analysis of cellular kinases
after treatment with Raf inhibitors confirmed the ability of some
Raf inhibitors to activate both Raf-1 and A-Raf. Recent literature
has demonstrated that B-Raf can form hetero-complexes with
both Raf-1 and A-Raf (Weber et al., 2001; Karreth et al., 2009).
Further, it has been demonstrated that occupancy of the ATP
site of a Raf kinase involved in a Raf-Raf dimer can cause trans-
activation of the binding partner (Poulikakos et al., 2010). Two
aspects of the data presented here are particularly interesting
given this recent literature on the subject. First, PLX4720,
which was the only compound found in our studies to be
a functional inhibitor of A-Raf, also caused the most dramatic
A-Raf activation on cellular treatment. Thus it appears likely
that A-Raf transactivation occurs in a manner similar to what
has been reported for B- and Raf-1. Furthermore, A-Raf transac-
tivation may require direct binding to A-Raf, but may not occur
efficiently through B-Raf or Raf-1 ATP site occupancy. Second,
the data presented here clearly demonstrate that Raf transacti-
vation occurs in A375 cells, which contain the V600E B-Raf
mutation. In contrast, no reports to date have found any
evidence of Raf transactivation in V600E-B-Raf melanoma lines
based on p-ERK1/2, p-MAP2K1 levels and/or immunoprecipita-
tion functional assays. Functional transactivation, manifested as
increased p-MAP2K1/p-ERK1/2 levels, has only been observed
in WT-B-Raf and WT-B-Raf/mutant-Ras containing cell lines.
It has been hypothesized that this unusual observation results
from decreased Ras expression in V600E-B-Raf expressing
cells that would prevent the formation of Raf homo- and699–710, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 707
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In Situ Native Kinase Profilinghetero-dimers (Poulikakos et al., 2010). Our results show,
however, that an aspect of transactivation, possibly
a conformational change leading to increased ATP affinity,
does occur even in V600E-B-Raf cellular background. Thus,
Raf dimers likely exist in these cells and exhibit similar properties
to their counterparts inWT-B-Raf backgrounds. The failure of the
Raf molecular transactivation event to enhance ERK pathway
signaling in V600E-B-Raf cells may be due to differences in
cellular context not related to the presence/absence of Raf
dimers (but possibly still related to Ras expression/activity).
The ability of this platform to directly monitor conformational/
activation events in kinase signaling pathways is a unique and
powerful advantage for deciphering complex kinase biology.
Overall the platform detailed here provides a powerful tool to
globally study the behavior of kinases in a nearly-intact cellular
context. This platform enables quantitative assessment of nearly
all protein and lipid kinases in any given cell or tissue type
and permits determination of small molecule/kinase affinity for
native enzymes with endogenous binding partners and post-
translational modifications intact. The platform is also species
independent as long as protein sequence information is available
for the organism of interest. The specific data presented here
provide the most complete picture of native kinase ATP and
inhibitor specificity presented to date. From these data it is clear
that cellular kinases are regulated through mechanisms that are
not currently accounted for in recombinant assay systems. The
KiNativ platform provides critical and relevant data to develop
selective and potent kinase inhibitors and/or assess the in vivo
function of kinases.
SIGNIFICANCE
Protein kinases are the largest and one of the most impor-
tant enzyme families in mammals. The KiNativ platform
described here is streamlined for global profiling of kinase
ATP-binding sites directly in cell and tissue lysates. Binding
constants for ATP, staurosporine, and five advanced or
clinical-stage kinase inhibitors were determined in two
different cell types. In general, the data support the known
properties of kinase inhibitors, however, some striking
differences from recombinant assay data were observed.
In the Raf kinase family, the activity of inhibitors against
recombinant Raf kinases were found to show almost no
correlation with binding to native Raf kinases. For B-Raf
signaling it was demonstrated that native kinase binding
correlated very well with cellular inhibition of B-Raf
signaling. This result demonstrates that kinases in their
native environment can exist in distinct conformations that
are not accurately represented in purified/recombinant
kinase preparations. In several cases, inhibitor binding
constants were found to closely match the EC50 for cellular
activity. This result suggests that the cellular ATP levels
experienced by many protein kinases do not contribute
significantly to the reduced levels of potency in the cellular
setting. Many differences between inhibitor potency ob-
served between recombinant kinase assays and cellular
activity may be attributed simply to differences in the prop-
erties of the kinase targets in their native setting. These
results have important implications for the design of kinase708 Chemistry & Biology 18, 699–710, June 24, 2011 ª2011 Elseviertargeted therapeutics and also highlight the importance of
platforms like KiNativ that allow for detailed and compre-
hensive investigations of kinases in a native state.
EXPERIMENTAL PROCEDURES
ATP and ADP Acyl-Nucleotide Probes
ATPandADPAcyl-nucleotideprobesweresynthesizedasdescribedpreviously
except that desthiobiotin was substituted for biotin in all cases (Patricelli
et al., 2007). Additional information regarding purification conditions, nuclear
magnetic resonance data, etc. is located in the Supplemental Experimental
Procedures.
Lysate Preparation for Probe-Based Inhibitor Profiling
Cell pelletswere resuspended in four volumesof lysis buffer (25mMTris pH7.6,
150 mM NaCl, 1% CHAPS, 1% Tergitol NP-40 type, 1% v/v phosphatase
inhibitor cocktail II [EMD/Calbiochem, #524625]), sonicated using a tip
sonicator, and Dounce homogenized. Lysates were cleared by centrifugation
at 100,000 3 g for 30 min. The cleared lysates were filtered through
a 0.22 mM syringe filter, and gel filtered (BioRad 10DG) into reaction buffer
(20mMHEPES pH 7.8, 150mMNaCl, 0.1%Triton X-100, 1% v/v phosphatase
inhibitor cocktail II [EMD/Calbiochem, #524625]). MnCl2 was then added to the
lysate to a final concentration of 20 mM before inhibitor treatment and probe
labeling. Final inhibitor concentrations used for IC50 determinations were 10,
1, 0.1, and 0.01 mM. ATP competition experiments were performed at 1000,
100, 10, and 1 mM ATP. All inhibitor treatments were performed at room
temperature.
Recombinant Enzyme Samples
Recombinant ErbB2 (amino acids 679–1255) was obtained from Enzo Life
Sciences. Wild-type, full length B-Raf and V599E B-Raf (amino acids 416–
766) were obtained from Invitrogen. Raf-1 (amino acids 1–149) was obtained
from Millipore.
Preparation of Intact Membranes and Cellular Assay Conditions
Detailed information regarding membrane preparations and cellular assays is
located in the Supplemental Experimental Procedures.
Probe Labeling and Sample Preparation
Unless otherwise noted, all probe reactions were performed at room temper-
ature with a final probe concentration of 5 mM after a 15 min preincubation
of lysate with inhibitor. All reactions were performed in duplicate, using
445 ml/sample at 5 mg/ml. Samples were prepared for MS analysis essentially
as described previously (Okerberg et al., 2005). Briefly, probe-labeled lysates
were denatured and reduced (6 M urea, 10 mM DTT, 65C, 15 min), alkylated
(40 mM Iodoacetamide, 37C, 30 min), and gel filtered (BioRad 10DG) into
10 mM ammonium bicarbonate, 2 M urea, 5 mM methionine. The desalted
protein mixture was digested with trypsin (0.015 mg/ml) for 1 hr at 37C, and
desthiobiotinylated peptides captured using 12.5 ml high-capacity streptavidin
resin (Thermo Scientific). Captured peptides were then washed extensively
using 150 ml/washwith three different wash buffers: (A) 10 timeswith 1% triton,
0.5% tergitol, 1 mM EDTA in PBS; (B) 60 times with PBS; and (C) 15 times with
HPLC grade water. Peptides were eluted from the streptavidin beads using
two 35-ml washes of a 50% CH3CN/water mixture containing 0.1% TFA at
room temperature.
LC-MS/MS Analysis
Samples were analyzed by LC-MS/MS as described previously (Okerberg
et al., 2005). Detailed information regarding data collection is located in the
Supplemental Experimental Procedures.
Data Analysis
All MS data were analyzed using custom software that was designed to extract
and normalize signals from relevant probe-labeled peptides. Detailed informa-
tion regarding this process is located in the Supplemental Experimental
Procedures.Ltd All rights reserved
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app Values from KiNativ Determined IC50 Values
Detailed information regarding the determination of Kd
app is located in the
Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and six tables and can be found with this article online at
doi:10.1016/j.chembiol.2011.04.011.
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